Icatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase-induced orolingual angioedema.
acute ischemic stroke
alteplase
icatibant
orolingual angioedema
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
28 Dec 2023
28 Dec 2023
Historique:
revised:
17
11
2023
received:
29
10
2023
accepted:
22
11
2023
medline:
29
12
2023
pubmed:
29
12
2023
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Orolingual angioedema (OA) represents a rare but life-threatening complication among patients with acute ischemic stroke treated with intravenous thrombolysis with alteplase. Novel agents, including icatibant, are recommended in resistant patients with alteplase-induced OA who have failed to respond to first-line therapies including corticosteroids, antihistamines, and/or adrenaline. We present a patient with alteplase-induced OA who showed substantial clinical improvement following the administration of icatibant. We describe a 71-year-old woman with known arterial hypertension under treatment with angiotensin-converting enzyme inhibitor, who presented with acute ischemic stroke in the territory of the right middle cerebral artery and received intravenous alteplase. During intravenous thrombolysis, the case was complicated with OA without any response to standard anaphylactic treatment including corticosteroids, dimetindene, and adrenaline. Thirty minutes after symptom onset, icatibant, a synthetic selective bradykinin B2-receptor antagonist, was administered subcutaneously. Substantial symptomatic resolution was observed only following the icatibant administration. This case highlights the effectiveness of icatibant in the acute management of alteplase-induced OA. In particular, icatibant administration, following first-line therapies including corticosteroids, antihistamines, and/or adrenaline, may avert tracheostomy and intubation in resistant and refractory cases with OA following intravenous thrombolysis for acute ischemic stroke.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Orolingual angioedema (OA) represents a rare but life-threatening complication among patients with acute ischemic stroke treated with intravenous thrombolysis with alteplase. Novel agents, including icatibant, are recommended in resistant patients with alteplase-induced OA who have failed to respond to first-line therapies including corticosteroids, antihistamines, and/or adrenaline.
METHODS
METHODS
We present a patient with alteplase-induced OA who showed substantial clinical improvement following the administration of icatibant.
RESULTS
RESULTS
We describe a 71-year-old woman with known arterial hypertension under treatment with angiotensin-converting enzyme inhibitor, who presented with acute ischemic stroke in the territory of the right middle cerebral artery and received intravenous alteplase. During intravenous thrombolysis, the case was complicated with OA without any response to standard anaphylactic treatment including corticosteroids, dimetindene, and adrenaline. Thirty minutes after symptom onset, icatibant, a synthetic selective bradykinin B2-receptor antagonist, was administered subcutaneously. Substantial symptomatic resolution was observed only following the icatibant administration.
CONCLUSIONS
CONCLUSIONS
This case highlights the effectiveness of icatibant in the acute management of alteplase-induced OA. In particular, icatibant administration, following first-line therapies including corticosteroids, antihistamines, and/or adrenaline, may avert tracheostomy and intubation in resistant and refractory cases with OA following intravenous thrombolysis for acute ischemic stroke.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I-LXII. doi:10.1177/2396987321989865
Brown E, Campana C, Zimmerman J, Brooks S. Icatibant for the treatment of orolingual angioedema following the administration of tissue plasminogen activator. Am J Emerg Med. 2018;36(6):1125.e1-1125.e2. doi:10.1016/j.ajem.2018.03.018
Myslimi F, Caparros F, Dequatre-Ponchelle N, et al. Orolingual angioedema during or after thrombolysis for cerebral ischemia. Stroke. 2016;47(7):1825-1830. doi:10.1161/STROKEAHA.116.013334
Fröhlich K, Macha K, Gerner ST, et al. Angioedema in stroke patients with thrombolysis. Stroke. 2019;50(7):1682-1687. doi:10.1161/STROKEAHA.119.025260
Pahs L, Droege C, Kneale H, Pancioli A. A novel approach to the treatment of orolingual angioedema after tissue plasminogen activator administration. Ann Emerg Med. 2016;68(3):345-348. doi:10.1016/j.annemergmed.2016.02.019
Baş M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(5):418-425. doi:10.1056/NEJMoa1312524
Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532-541. doi:10.1056/NEJMoa0906393
Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010;56(3):278-282. doi:10.1016/j.annemergmed.2010.03.032
Cheong E, Dodd L, Smith W, Kleinig T. Icatibant as a potential treatment of life-threatening alteplase-induced angioedema. J Stroke Cerebrovasc Dis. 2018;27(2):e36-e37. doi:10.1016/j.jstrokecerebrovasdis.2017.09.039
Mas-Serrano M, Garcia-Pastor A, Tornero-Molina P, Vazquez-Alen P, Palacios-Mendoza MA, Gil-Nunez AC. Tratamiento del angioedema orolingual inducido por alteplasa mediante icatibant [Treatment of alteplase-induced orolingual angioedema by means of icatibant]. Rev Neurol. 2019;69(6):261-262. doi:10.33588/rn.6906.2019123
Wollmach AD, Zehnder D, Schwendinger M, Tarnutzer AA. Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant. BMJ Case Rep. 2020;13(12):e236643. doi:10.1136/bcr-2020-236643